Results 61 to 70 of about 12,119 (223)

Hypersomnia in Neuromyelitis Optica Spectrum Disorders

Türk Uyku Tıbbı Dergisi
Hypersomnolence or narcolepsy may be the initial finding in neuromyelitis optica spectrum disorders (NMOSD); therefore, it is important in clinical evaluation.
Hasan Can Güdek, Özdem Ertürk Çetin, İpek Güngör Doğan, Damla Çetinkaya Tezer, Serkan Demir   +4 more
doaj   +1 more source

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. [PDF]

, 2018
OBJECTIVE: We characterised the clinical course, treatment and outcomes in 59 patients with relapsing myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination.
Australasian and New Zealand MOG Study Group Andrews, P, Barnett, Mh, Barton, J, Brilot, F, Broadley, S, Burrow, J, Butzkueven, H, Cairns, A, Calvert, S, Caruana, P, Chelakkadan, S, Clark, D, Dale, Rc, Fraser, C, Freeman, J, Fung, Vsc, Gill, D, Grattan-Smith, P, Gupta, S, Hardy, T, Henderson, Apd, Kothur, K, Lechner-Scott, J, Ling, S, Lopez, J, Malone, S, Marriott, M, Merheb, V, Mohammad, S, Nguyen, Tk, Nosadini, M, O'grady, G, Orr, C, Ouvrier, R, Parratt, J, Patrick, E, Pilli, D, Ramanathan, S, Reddel, Sw, Riminton, D, Riney, K, Rodriguez-Casero, V, Ryan, M, Scheffer, I, Shah, U, Shuey, N, Spooner, C, Subramanian, G, Tantsis, E, Tea, F, Thomas, T, Thompson, J, Troedson, C, Vucic, S, Ware, T, Webster, R, White, Ob, Yiannikas, C, Yiu, E, Zou, A.   +59 more
core   +1 more source

Post-COVID Neuromyelitis Optica Spectrum Disorder

Journal of the College of Physicians and Surgeons Pakistan, 2021
After novel coronavirus pandemic that emerged from Wuhan, China in December 2019, several cases of inflammatory and immune-mediated disorders have been reported, thought to be triggered by SARS-CoV-2 infection. Neuromyelitis optica spectrum disorder (NMOSD) is one of the autoimmune demyelinating disorders, which is thought to be triggered by viral ...
Shumaila, Rafique, Areeba, Wasim, Tipu, Sultan, Arsalan, Ahmad   +3 more
openaire   +3 more sources

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Neuromyelitis optica spectrum disorders in children

Неврология, нейропсихиатрия, психосоматика
In recent decades, the prevalence of demyelinating diseases in paediatric patients has increased rapidly. In this context, there is an increasing need for the study of this pathology in children to enable timely diagnosis and early prescription of highly
N. F. Akhmetgaleeva, T. O. Simaniv, E. M. Yausheva, Yа. A. Saitova, O. V. Lyutov, M. A. Kutlubaev, K. Z. Bakhtiyarova   +6 more
doaj   +1 more source

Brainstem involvement - frequency, presentation and outcome [PDF]

, 2016
Background Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) are present in a subset of aquaporin-4 (AQP4)-IgG-negative patients with optic neuritis (ON) and/or myelitis.
Jarius, Sven, Kleiter, Ingo, Ruprecht, Klemens   +2 more
core   +1 more source

Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders. [PDF]

PLoS ONE, 2013
Autoantibodies against aquaporin-4 (AQP4), a water channel in CNS astrocytes, are detected in ∼50-80% of patients with neuromyelitis optica spectrum disorders (NMOsd), characterized by longitudinally extensive transverse myelitis (LETM) and/or optic ...
John S Tzartos, Christos Stergiou, Konstantinos Kilidireas, Paraskevi Zisimopoulou, Thomas Thomaidis, Socrates J Tzartos   +5 more
doaj   +1 more source

Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. [PDF]

, 2016
Alemtuzumab is an anti-CD52 monoclonal antibody recently licensed for use in relapsing-remitting multiple sclerosis. Here, we report our experience of its use in neuromyelitis optica (NMO) spectrum disorders.
Azzopardi, L, Coles, AJ, Cox, AL, Jones, JL, McCarthy, CL   +4 more
core   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Therapeutic decision making in autoimmune and inflammatory disorders of the central nervous system in children. [PDF]

, 2016
Autoimmune and inflammatory disorders of the central nervous system can result in significant morbidity and mortality. Through the recognition of syndromes using diagnostic biomarkers, the clinician is now able to use immune suppressive therapies to ...
Dale, Rc, Lim, M., Nosadini, M
core   +3 more sources